Delays in Core Laboratory Testing, Monday, January 22, 2018

On Monday, January 22, 2018, instrumentation in the core clinical laboratory will be undergoing required maintenance from approximately 09:30 – 15:00. This will delay the resulting of the following assays in that time window:

Amikacin drug level [LAB555]
Carbamazepine drug level [LAB22]
Ceruloplasmin [LAB582]
Drug of abuse – urine screens [LAB500 and LAB1032]
Ethylene glycol, plasma (by immunoassay) [LAB7453]
Everolimus drug level [LAB7456]
Haptoglobin [LAB89]
Homocysteine [LAB93]
IgA [LAB73]
IgG [LAB71]
IgM [LAB72]
Keppra (levetiracetam) drug level [LAB477]
Lamotrigine (Lamictal) drug level (LAB475]
Lidocaine drug level [LAB641]
Methotrexate drug level [LAB481]
Nicotine metabolite, rapid screen [LAB8071]
Pentobarbital drug level [LAB656]
Phenobarbital drug level [LAB30]
Phenytoin free drug level [LAB32]
Rheumatoid factor [LAB206]
THC urine screen [LAB5203]
THC urine screen with reflexed confirmation [LAB7388]
Theophylline drug level [LAB35]
Tobramycin drug level [LAB36]
Valproic acid drug level [LAB25]

Questions should be directed to Matthew Krasowski, MD, PhD, medical director of the Clinical Chemistry Laboratory (384-9380,